v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Summarized Financial Information of Equity Method Investee (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]      
Current assets $ 42,898 $ 50,358  
Total assets 208,160 213,396  
Current liabilities 36,984 42,995  
Total liabilities 121,385 124,899  
Total Pfizer Inc. shareholders’ equity 86,476 88,203  
Equity Method Investment, Summarized Financial Information [Abstract]      
Revenues: [1] 62,579 63,627 $ 59,553
Income from continuing operations 7,787 8,051 2,172
Net income 7,812 8,062 2,158
Income attributable to shareholders 7,771 8,031 2,119
ViiV [Member]      
Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]      
Current assets 4,991 4,338  
Noncurrent assets 3,297 3,223  
Total assets 8,288 7,561  
Current liabilities 4,714 4,280  
Noncurrent liabilities 5,735 6,205  
Total liabilities 10,449 10,485  
Total Pfizer Inc. shareholders’ equity (2,161) (2,924)  
Equity Method Investment, Summarized Financial Information [Abstract]      
Revenues: 9,824 8,971 7,845
Cost of sales (1,637) (1,360) (1,060)
Gross profit 8,187 7,611 6,785
Income from continuing operations 4,277 3,062 3,090
Net income 4,277 3,062 3,090
Income attributable to shareholders $ 4,277 $ 3,062 $ 3,090
[1] Revenues are primarily attributed to countries based on the location of the customer.